Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Plasma cell 8Other hematologic neoplasm 7Sarcoma 6Lymphoid 6Gastrointestinal 6Gynecologic 5Dermatologic 4CNS 3Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 38Radiotherapy 35Magnetic Resonance Spectroscopy 32Specimen Handling 22Cetuximab 18Fluorouracil 17Radiotherapy, Intensity-Modulated 16Platinum 161,2-diaminocyclohexaneplatinum II citrate 16Biopsy 15Paclitaxel 13Carboplatin 13Nivolumab 11Docetaxel 10pembrolizumab 8Radiation 8Fluorodeoxyglucose F18 8Erlotinib Hydrochloride 8Bortezomib 8Bevacizumab 8Gemcitabine 7Sorafenib 6Immunoglobulin G 6Disulfides 6aldesleukin 5Hydroxyurea 5Gefitinib 5Chemotherapy, Adjuvant 5(225)Ac-DOTA-c(RGDyK) 5cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thalidomide × Head & Neck × Clear all
NCT00003850 2013-02-08

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡